[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @spontonic Spontonic Spontonic posts on X about $chrs, $pfe, $mrk, $4507t the most. They currently have XXX followers and XX posts still getting attention that total X engagements in the last XX hours. ### Engagements: X [#](/creator/twitter::38920802/interactions)  - X Week XXX +67% - X Month XXXXX -XX% - X Months XXXXXX +140% - X Year XXXXXX +124% ### Mentions: X [#](/creator/twitter::38920802/posts_active)  - X Week XX +275% - X Month XX -XX% - X Months XXX +120% - X Year XXX +105% ### Followers: XXX [#](/creator/twitter::38920802/followers)  - X Week XXX +0.14% - X Month XXX +0.14% - X Months XXX +5.40% - X Year XXX -XXXX% ### CreatorRank: undefined [#](/creator/twitter::38920802/influencer_rank)  ### Social Influence [#](/creator/twitter::38920802/influence) --- **Social category influence** [stocks](/list/stocks) XXX% [travel destinations](/list/travel-destinations) XXXX% **Social topic influence** [$chrs](/topic/$chrs) 16.28%, [$pfe](/topic/$pfe) 4.65%, [$mrk](/topic/$mrk) 4.65%, [$4507t](/topic/$4507t) 2.33%, [good news](/topic/good-news) 2.33%, [$cmpx](/topic/$cmpx) 2.33%, [attention to](/topic/attention-to) 2.33%, [applications](/topic/applications) 2.33%, [$smmt](/topic/$smmt) 2.33%, [shanghai](/topic/shanghai) XXXX% **Top accounts mentioned or mentioned by** [@tparmalee](/creator/undefined) [@qniatof](/creator/undefined) [@biotechbeast](/creator/undefined) [@oldgrapex](/creator/undefined) [@coherusbio](/creator/undefined) [@chrisintroy](/creator/undefined) [@biotech_beast](/creator/undefined) [@oneworld1383](/creator/undefined) **Top assets mentioned** [Pfizer, Inc. (PFE)](/topic/$pfe) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [Sanofi (SNY)](/topic/sanofi) ### Top Social Posts [#](/creator/twitter::38920802/posts) --- Top posts by engagements in the last XX hours "Anti-#CCR8 MAb S-531011 Shionogi" [X Link](https://x.com/spontonic/status/1975669459089326415) [@spontonic](/creator/x/spontonic) 2025-10-07T21:07Z XXX followers, XXX engagements "Never even gave TIGIT a glance. Didn't buy into any of them post-brief CD47 flirtation. I'm not a groupie. Anti-#CCR8 is designed to work without inducing autoimmunity and preclinical and clinical results to date are encouraging. For me any good CCR8 news is $CHRS good news" [X Link](https://x.com/spontonic/status/1952461716555698351) [@spontonic](/creator/x/spontonic) 2025-08-04T20:08Z XXX followers, 1113 engagements "3/ For example $PFE knows how much it needs a good CCR8. Dias et al. have been quick and bright $CHRS is in the mix. So. co-develop XXX exclusive. send that tori salesforce out to sell that An aside. STORM has venture ties with PFE" [X Link](https://x.com/spontonic/status/1953627067607920880) [@spontonic](/creator/x/spontonic) 2025-08-08T01:19Z XXX followers, XXX engagements "$CHRS more on casdo relevant theme. "interleukin-27 receptor is essential for tumor growth control mediated by Stub1/Chic2 knockout CD8+ T cells"" [X Link](https://x.com/spontonic/status/1955652107689918641) [@spontonic](/creator/x/spontonic) 2025-08-13T15:26Z XXX followers, XXX engagements "$CHRS $PFE $MRK $CMPX More on companies that need CHS-114. "It hardly needs stating that biopharma has staked huge sums on PD-(L)1 x VEGF bispecifics". All of the molecules mentioned will need life extension plans" [X Link](https://x.com/spontonic/status/1955665399061807304) [@spontonic](/creator/x/spontonic) 2025-08-13T16:19Z XXX followers, XXX engagements "INOVIO INOVIO INOVIO SALES FORCE SALES FORCE SALES FORCE Clown virtually had tori standing on INOVIO's shoulders. It's still a focal point in slides Now he has plans to stand tori on 114's shoulders in the U.S. all while spending $XX to sell $X of it. $CHRS" [X Link](https://x.com/spontonic/status/1956101981053051250) [@spontonic](/creator/x/spontonic) 2025-08-14T21:13Z XXX followers, XXX engagements "Merck's footprints. clinical trial supply agreements (that won't look remotely practical to most potential partners) And the BOD does nothing. $CHRS $MRK" [X Link](https://x.com/spontonic/status/1956103820649619497) [@spontonic](/creator/x/spontonic) 2025-08-14T21:21Z XXX followers, XXX engagements "$CHRS "We can't seem to sell tori. I don't understand it but we need to rebrand the sales team. From this day on it's a sales FORCE Thank you for your attention to this matter."" [X Link](https://x.com/spontonic/status/1958231233961529810) [@spontonic](/creator/x/spontonic) 2025-08-20T18:14Z XXX followers, XXX engagements "Would love to see Fleetwood win it all. "making #CCR8 and similar proteins more tractable for biochemical studies antibody development and therapeutic applications"" [X Link](https://x.com/spontonic/status/1959312669724274861) [@spontonic](/creator/x/spontonic) 2025-08-23T17:51Z XXX followers, XXX engagements "#CCR8 Shimon Sakaguchi and the Nobel Prize in Physiology or Medicine 2025. among other accomplishments" [X Link](https://x.com/spontonic/status/1975304706726715424) [@spontonic](/creator/x/spontonic) 2025-10-06T20:58Z XXX followers, XXX engagements ""The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1 and thereby attain better enrichment in the tumor microenvironment". at a cost of a little more tox than other anti-PD-1 Fabs" [X Link](https://x.com/spontonic/status/1979229400139993103) [@spontonic](/creator/x/spontonic) 2025-10-17T16:53Z XXX followers, XXX engagements "Sort of figured. But of course AI agents do make mistakes and can't predict a future shaped by existing but unforeseen biology. Junshi attempting to use tori's own Fab to cut into its partner's sales" [X Link](https://x.com/spontonic/status/1979251392520032376) [@spontonic](/creator/x/spontonic) 2025-10-17T18:21Z XXX followers, XX engagements "Amgen v. Sanofi: The 2023 Supreme Court ruling in Amgen v. Sanofi affirmed the need for patents to sufficiently enable the full scope of a claimed invention reinforcing the idea that broad speculative claims are not valid. By analogy a license" [X Link](https://x.com/spontonic/status/1979252764279792010) [@spontonic](/creator/x/spontonic) 2025-10-17T18:26Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@spontonic Spontonic
Spontonic posts on X about $chrs, $pfe, $mrk, $4507t the most. They currently have XXX followers and XX posts still getting attention that total X engagements in the last XX hours.
Engagements: X #
- X Week XXX +67%
- X Month XXXXX -XX%
- X Months XXXXXX +140%
- X Year XXXXXX +124%
Mentions: X #
- X Week XX +275%
- X Month XX -XX%
- X Months XXX +120%
- X Year XXX +105%
Followers: XXX #
- X Week XXX +0.14%
- X Month XXX +0.14%
- X Months XXX +5.40%
- X Year XXX -XXXX%
CreatorRank: undefined #
Social Influence #
Social category influence stocks XXX% travel destinations XXXX%
Social topic influence $chrs 16.28%, $pfe 4.65%, $mrk 4.65%, $4507t 2.33%, good news 2.33%, $cmpx 2.33%, attention to 2.33%, applications 2.33%, $smmt 2.33%, shanghai XXXX%
Top accounts mentioned or mentioned by @tparmalee @qniatof @biotechbeast @oldgrapex @coherusbio @chrisintroy @biotech_beast @oneworld1383
Top assets mentioned Pfizer, Inc. (PFE) Merck & Co., Inc. (MRK) Summit Therapeutics Inc. Common Stock (SMMT) Sanofi (SNY)
Top Social Posts #
Top posts by engagements in the last XX hours
"Anti-#CCR8 MAb S-531011 Shionogi"
X Link @spontonic 2025-10-07T21:07Z XXX followers, XXX engagements
"Never even gave TIGIT a glance. Didn't buy into any of them post-brief CD47 flirtation. I'm not a groupie. Anti-#CCR8 is designed to work without inducing autoimmunity and preclinical and clinical results to date are encouraging. For me any good CCR8 news is $CHRS good news"
X Link @spontonic 2025-08-04T20:08Z XXX followers, 1113 engagements
"3/ For example $PFE knows how much it needs a good CCR8. Dias et al. have been quick and bright $CHRS is in the mix. So. co-develop XXX exclusive. send that tori salesforce out to sell that An aside. STORM has venture ties with PFE"
X Link @spontonic 2025-08-08T01:19Z XXX followers, XXX engagements
"$CHRS more on casdo relevant theme. "interleukin-27 receptor is essential for tumor growth control mediated by Stub1/Chic2 knockout CD8+ T cells""
X Link @spontonic 2025-08-13T15:26Z XXX followers, XXX engagements
"$CHRS $PFE $MRK $CMPX More on companies that need CHS-114. "It hardly needs stating that biopharma has staked huge sums on PD-(L)1 x VEGF bispecifics". All of the molecules mentioned will need life extension plans"
X Link @spontonic 2025-08-13T16:19Z XXX followers, XXX engagements
"INOVIO INOVIO INOVIO SALES FORCE SALES FORCE SALES FORCE Clown virtually had tori standing on INOVIO's shoulders. It's still a focal point in slides Now he has plans to stand tori on 114's shoulders in the U.S. all while spending $XX to sell $X of it. $CHRS"
X Link @spontonic 2025-08-14T21:13Z XXX followers, XXX engagements
"Merck's footprints. clinical trial supply agreements (that won't look remotely practical to most potential partners) And the BOD does nothing. $CHRS $MRK"
X Link @spontonic 2025-08-14T21:21Z XXX followers, XXX engagements
"$CHRS "We can't seem to sell tori. I don't understand it but we need to rebrand the sales team. From this day on it's a sales FORCE Thank you for your attention to this matter.""
X Link @spontonic 2025-08-20T18:14Z XXX followers, XXX engagements
"Would love to see Fleetwood win it all. "making #CCR8 and similar proteins more tractable for biochemical studies antibody development and therapeutic applications""
X Link @spontonic 2025-08-23T17:51Z XXX followers, XXX engagements
"#CCR8 Shimon Sakaguchi and the Nobel Prize in Physiology or Medicine 2025. among other accomplishments"
X Link @spontonic 2025-10-06T20:58Z XXX followers, XXX engagements
""The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1 and thereby attain better enrichment in the tumor microenvironment". at a cost of a little more tox than other anti-PD-1 Fabs"
X Link @spontonic 2025-10-17T16:53Z XXX followers, XXX engagements
"Sort of figured. But of course AI agents do make mistakes and can't predict a future shaped by existing but unforeseen biology. Junshi attempting to use tori's own Fab to cut into its partner's sales"
X Link @spontonic 2025-10-17T18:21Z XXX followers, XX engagements
"Amgen v. Sanofi: The 2023 Supreme Court ruling in Amgen v. Sanofi affirmed the need for patents to sufficiently enable the full scope of a claimed invention reinforcing the idea that broad speculative claims are not valid. By analogy a license"
X Link @spontonic 2025-10-17T18:26Z XXX followers, XX engagements